RU2543620C2 - Производные урацила или тимина для лечения гепатита с - Google Patents
Производные урацила или тимина для лечения гепатита с Download PDFInfo
- Publication number
- RU2543620C2 RU2543620C2 RU2010114828/04A RU2010114828A RU2543620C2 RU 2543620 C2 RU2543620 C2 RU 2543620C2 RU 2010114828/04 A RU2010114828/04 A RU 2010114828/04A RU 2010114828 A RU2010114828 A RU 2010114828A RU 2543620 C2 RU2543620 C2 RU 2543620C2
- Authority
- RU
- Russia
- Prior art keywords
- tert
- butyl
- dioxotetrahydropyrimidin
- group
- phenyl
- Prior art date
Links
- 0 *c1cc(N(C(*)=C(*)C(N2*)=O)C2=O)cc(*)c1* Chemical compound *c1cc(N(C(*)=C(*)C(N2*)=O)C2=O)cc(*)c1* 0.000 description 17
- XNYKCPSGPBBQBQ-JLQKSHHBSA-N CC(C)(C)c(cc(cc1NC(c(cc2)ccc2NS(C)(=O)=O)=O)/C(/CCCC(CC2=N)=O)=C\C2=O)c1OC Chemical compound CC(C)(C)c(cc(cc1NC(c(cc2)ccc2NS(C)(=O)=O)=O)/C(/CCCC(CC2=N)=O)=C\C2=O)c1OC XNYKCPSGPBBQBQ-JLQKSHHBSA-N 0.000 description 1
- IGHHIJGOIDFCFW-OMSIOKFJSA-N CC(C)(C)c1cc(/C(/CCCC(CC2=N)=O)=C\C2=O)cc(C#Cc2c(CNS=O)cccn2)c1OC Chemical compound CC(C)(C)c1cc(/C(/CCCC(CC2=N)=O)=C\C2=O)cc(C#Cc2c(CNS=O)cccn2)c1OC IGHHIJGOIDFCFW-OMSIOKFJSA-N 0.000 description 1
- WPFLYXZIWPSJBA-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2cc3ncc(NSC)nc3cc2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2cc3ncc(NSC)nc3cc2)c1OC WPFLYXZIWPSJBA-UHFFFAOYSA-N 0.000 description 1
- QFNWRWSMBBUABM-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(C(CC3)NS(C)(=O)=O)c3c2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(C(CC3)NS(C)(=O)=O)c3c2)c1OC QFNWRWSMBBUABM-UHFFFAOYSA-N 0.000 description 1
- DGTXGWLRWHJWAO-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc3nc(-[n]4c(C)ccc4C)[s]c3c2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc3nc(-[n]4c(C)ccc4C)[s]c3c2)c1OC DGTXGWLRWHJWAO-UHFFFAOYSA-N 0.000 description 1
- ZYQGLTZMFGKEDJ-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc3nc(NS=O)[s]c3c2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc3nc(NS=O)[s]c3c2)c1OC ZYQGLTZMFGKEDJ-UHFFFAOYSA-N 0.000 description 1
- WQFKBVALGPRPPV-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(N(CCc2c3)Cc2ccc3NSC)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(N(CCc2c3)Cc2ccc3NSC)c1OC WQFKBVALGPRPPV-UHFFFAOYSA-N 0.000 description 1
- ZKBISQZXGWNNJF-RMKNXTFCSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C/c(cc2)ccc2OC)c1OC Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C/c(cc2)ccc2OC)c1OC ZKBISQZXGWNNJF-RMKNXTFCSA-N 0.000 description 1
- CUTIIZCDHVRSIE-UHFFFAOYSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(COc(cc2)ccc2N)c1OC Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(COc(cc2)ccc2N)c1OC CUTIIZCDHVRSIE-UHFFFAOYSA-N 0.000 description 1
- LLXDDUTVWPFUJE-UHFFFAOYSA-N CCCC(OCN(c(cc1)ccc1NC(c(cc(cc1C(C)(C)C)N(CCC(N2COC(CCC)=O)=O)C2=O)c1OC)=O)/S(/C)=C\C)=O Chemical compound CCCC(OCN(c(cc1)ccc1NC(c(cc(cc1C(C)(C)C)N(CCC(N2COC(CCC)=O)=O)C2=O)c1OC)=O)/S(/C)=C\C)=O LLXDDUTVWPFUJE-UHFFFAOYSA-N 0.000 description 1
- CFNHVUGPXZUTRR-UHFFFAOYSA-N CCCNCCN Chemical compound CCCNCCN CFNHVUGPXZUTRR-UHFFFAOYSA-N 0.000 description 1
- DIPWXBIVAXCYIP-SCSAIBSYSA-N CCN[C@H](C1)[I]1O Chemical compound CCN[C@H](C1)[I]1O DIPWXBIVAXCYIP-SCSAIBSYSA-N 0.000 description 1
- UZAAZICNWHJGFD-SZXQPVLSSA-N COc(c(-c1ccc[o]1)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccc(CC/C2=N\NS(C)(=O)=O)c2c1 Chemical compound COc(c(-c1ccc[o]1)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccc(CC/C2=N\NS(C)(=O)=O)c2c1 UZAAZICNWHJGFD-SZXQPVLSSA-N 0.000 description 1
- WTLGVHMLSDGNGC-SZXQPVLSSA-N COc(c(-c1ccc[s]1)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccc(CC/C2=N\NS(C)(=O)=O)c2c1 Chemical compound COc(c(-c1ccc[s]1)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccc(CC/C2=N\NS(C)(=O)=O)c2c1 WTLGVHMLSDGNGC-SZXQPVLSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US60/972,877 | 2007-09-17 | ||
| US9679108P | 2008-09-13 | 2008-09-13 | |
| US61/096,791 | 2008-09-13 | ||
| PCT/US2008/076576 WO2009039127A1 (en) | 2007-09-17 | 2008-09-17 | Uracil or thymine derivative for treating hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013104270/04A Division RU2599635C2 (ru) | 2007-09-17 | 2013-02-01 | Производные урацила или тимина для лечения гепатита с |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010114828A RU2010114828A (ru) | 2011-10-27 |
| RU2543620C2 true RU2543620C2 (ru) | 2015-03-10 |
Family
ID=39948002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114828/04A RU2543620C2 (ru) | 2007-09-17 | 2008-09-17 | Производные урацила или тимина для лечения гепатита с |
| RU2013104270/04A RU2599635C2 (ru) | 2007-09-17 | 2013-02-01 | Производные урацила или тимина для лечения гепатита с |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013104270/04A RU2599635C2 (ru) | 2007-09-17 | 2013-02-01 | Производные урацила или тимина для лечения гепатита с |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (en:Method) |
| EP (2) | EP2222646B1 (en:Method) |
| JP (2) | JP5734654B2 (en:Method) |
| KR (2) | KR101552474B1 (en:Method) |
| CN (2) | CN102746239B (en:Method) |
| AR (2) | AR070027A1 (en:Method) |
| AU (1) | AU2008302448B2 (en:Method) |
| BR (1) | BRPI0816994B8 (en:Method) |
| CA (2) | CA2976793A1 (en:Method) |
| CL (2) | CL2008002794A1 (en:Method) |
| CO (1) | CO6260076A2 (en:Method) |
| CR (2) | CR11316A (en:Method) |
| DO (2) | DOP2010000084A (en:Method) |
| ES (1) | ES2453591T3 (en:Method) |
| GT (1) | GT201000061A (en:Method) |
| IL (1) | IL204547A (en:Method) |
| IN (1) | IN2012DN05113A (en:Method) |
| MX (2) | MX2010002905A (en:Method) |
| MY (1) | MY162760A (en:Method) |
| NZ (3) | NZ618277A (en:Method) |
| PA (1) | PA8796201A1 (en:Method) |
| PE (2) | PE20090705A1 (en:Method) |
| PH (1) | PH12013500365A1 (en:Method) |
| RU (2) | RU2543620C2 (en:Method) |
| SG (1) | SG183733A1 (en:Method) |
| TW (2) | TWI534137B (en:Method) |
| UA (1) | UA117800C2 (en:Method) |
| UY (1) | UY31344A1 (en:Method) |
| WO (1) | WO2009039127A1 (en:Method) |
| ZA (2) | ZA201204224B (en:Method) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2639226B1 (en) * | 2007-09-17 | 2016-08-31 | AbbVie Bahamas Ltd. | Anti-infective pyrimidines and uses thereof |
| MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
| KR101552474B1 (ko) | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| MX2010005356A (es) * | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
| CN102099335A (zh) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| JP2012503620A (ja) | 2008-09-26 | 2012-02-09 | エフ．ホフマン−ラ ロシュ アーゲー | Ｈｃｖを処置するためのピリンまたはピラジン誘導体 |
| JP5744003B2 (ja) * | 2009-03-24 | 2015-07-01 | アッヴィ・バハマズ・リミテッド | 抗ウイルス化合物を調製する方法 |
| CN102448952B (zh) * | 2009-03-25 | 2014-10-29 | Abbvie公司 | 抗病毒化合物和其用途 |
| JP2012522013A (ja) * | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| AU2010240888A1 (en) | 2009-04-25 | 2011-11-17 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| AU2010264802A1 (en) * | 2009-06-24 | 2012-01-19 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| BR112012005616A2 (pt) | 2009-09-21 | 2016-06-21 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| CN102639504A (zh) * | 2009-11-21 | 2012-08-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| TW201144298A (en) * | 2009-12-14 | 2011-12-16 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| US9216952B2 (en) * | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| BR112013000245A2 (pt) | 2010-07-07 | 2016-05-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| MX2013000623A (es) * | 2010-07-16 | 2013-06-13 | Abbvie Inc | Proceso para la preparación de compuestos antivirales. |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US8841487B2 (en) | 2010-07-16 | 2014-09-23 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| RU2572835C2 (ru) | 2010-08-13 | 2016-01-20 | Ф. Хоффманн-Ля Рош Аг | Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| EP2685964A1 (en) | 2011-03-18 | 2014-01-22 | AbbVie Inc. | Formulations of phenyl uracil compounds |
| JP2014510743A (ja) * | 2011-03-31 | 2014-05-01 | シェファー、コンスタンツェ | 核酸の非ウイルスの導入のためのパーフルオロ化化合物 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| JP5709999B2 (ja) | 2011-08-01 | 2015-04-30 | 大日本住友製薬株式会社 | ウラシル誘導体およびその医薬用途 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| AP3613A (en) | 2012-05-15 | 2016-02-29 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1 |
| BR112014027244A2 (pt) | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 |
| MX2014013373A (es) | 2012-05-15 | 2015-08-14 | Novartis Ag | Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1. |
| US9315489B2 (en) | 2012-05-15 | 2016-04-19 | Novartis Ag | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| CA2876496A1 (en) | 2012-06-27 | 2014-01-03 | Abbvie Inc. | Methods for treating hcv |
| WO2014031791A1 (en) | 2012-08-21 | 2014-02-27 | Abbvie Inc. | Process for preparing antiviral compounds |
| BR112015008927A2 (pt) | 2012-10-18 | 2017-07-04 | Abbvie Inc | formulações de compostos derivados de pirimidinadiona |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| CA2916912A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| ES2728531T3 (es) | 2013-07-08 | 2019-10-25 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con C-N como agentes para combatir parásitos |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| CN105940002B (zh) | 2014-02-03 | 2018-09-25 | 生命医药公司 | ROR-γ的二氢吡咯并吡啶抑制剂 |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| CN106573915B (zh) | 2014-08-01 | 2020-12-25 | 纽韦卢森公司 | 针对布罗莫结构域有活性的化合物 |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| DK3207043T6 (da) | 2014-10-14 | 2020-01-20 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridin-inhibitorer af ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| JP2018525371A (ja) * | 2015-07-30 | 2018-09-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリール置換された二環式ヘテロアリール化合物 |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| AU2016355710B2 (en) | 2015-11-20 | 2021-03-25 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| SG11202000621VA (en) | 2017-07-24 | 2020-02-27 | Vitae Pharmaceuticals Llc | Inhibitors of ror? |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| JP7252973B2 (ja) | 2018-03-26 | 2023-04-05 | ノバルティス アーゲー | Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ベンズアミド誘導体 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| US20220387602A1 (en) * | 2019-09-16 | 2022-12-08 | Novartis Ag | Bifunctional degraders and their methods of use |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2040523C1 (ru) * | 1990-12-05 | 1995-07-25 | Ниссан Кемикал Индастриз, Лтд. | Производное урацила |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| US20060116390A1 (en) * | 2003-06-13 | 2006-06-01 | Jae-Hong Lim | Hepatitis c virus inhibitors |
| EA007178B1 (ru) * | 2000-05-23 | 2006-08-25 | Айденикс (Кайман) Лимитед | Производные beta-d-нуклеозида в качестве лекарственного средства для лечения инфекции вируса гепатита c у хозяина |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| DE69129998T2 (de) | 1990-02-15 | 1998-12-24 | Takeda Chemical Industries, Ltd., Osaka | Pyrimidindionderivate, deren Herstellung und Verwendung |
| NL9001075A (en:Method) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| RU2266901C2 (ru) | 1999-12-06 | 2005-12-27 | Ф.Хоффманн-Ля Рош Аг | 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167954A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | History of pyrimidine |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TWI394747B (zh) * | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| EP2639226B1 (en) * | 2007-09-17 | 2016-08-31 | AbbVie Bahamas Ltd. | Anti-infective pyrimidines and uses thereof |
| MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
| KR101552474B1 (ko) | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| CN102099335A (zh) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
-
2008
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2040523C1 (ru) * | 1990-12-05 | 1995-07-25 | Ниссан Кемикал Индастриз, Лтд. | Производное урацила |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| EA007178B1 (ru) * | 2000-05-23 | 2006-08-25 | Айденикс (Кайман) Лимитед | Производные beta-d-нуклеозида в качестве лекарственного средства для лечения инфекции вируса гепатита c у хозяина |
| US20060116390A1 (en) * | 2003-06-13 | 2006-06-01 | Jae-Hong Lim | Hepatitis c virus inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| R.D. FRANCESCO ET AL., Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase, Antiviral Research, 58, 2003, pp.1-16 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2543620C2 (ru) | Производные урацила или тимина для лечения гепатита с | |
| RU2539570C2 (ru) | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения | |
| RU2542099C2 (ru) | N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv) | |
| AU2014280939B2 (en) | Uracil or thymine derivative for treating hepatitis C | |
| AU2013202002A1 (en) | Uracil or thymine derivative for treating hepatitis C | |
| UA104995C2 (uk) | Похідні урацилу або тиміну для лікування гепатиту с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200918 |